News Contact Us

Biocon Biologics buys Pfizer Healthcare’s Chennai research facility

Author : Pankaj Singh | Published Date : 2019-09-25 

For the past few years, the pharmaceutical industry has witnessed an exponential growth across the globe. With various scientific innovations being conducted worldwide, companies have now started to expand their research capabilities by means of effective expansion strategies and acquisitions.

One such stride was made recently by Biocon Ltd., a leading biopharmaceutical company in Asia, when it revealed that its subsidiary, Biocon Biologics Ltd., has acquired Pfizer Healthcare’s biological research facility in Chennai for an undisclosed amount.

According to reliable sources, the buyout included the acquisition of R&D capital assets of a research facility spread over 60,000 sq. ft at the TICEL Bio Park in Chennai.

Speaking on the acquisition, Christiane Hamacher, CEO, Biocon Biologics, said that the Chennai-based R&D facility will allow their firm to grow its R&D capability and advance its motive to achieve its strategic long-term goals of fulfilling the requirements of millions of patients present across the globe.

Moreover, this investment will push the development of its biosimilars, taking it from lab to pilot scale, cites Hamacher.

Reportedly, the facility will house an early-stage innovation and research center that includes drug product formulation and analytical R&D laboratories as well as a pilot-scale R&D unit stocked with cell line development. Moreover, it is likely to be operational following post qualification and will accommodate around 250 scientists.

Sources cite that the purchase would offer a significant time advantage to the company and will develop the global advancements of its biosimilars portfolio.

Incidentally, Biocon has also been active in China, a promising market for pharmaceuticals. In a bid to enhance its presence, the company signed a supply and license agreement for the formulation of three Generic products with a subsidiary of China Medical System Holdings Ltd. (CMS).

Reportedly, the move comes at the foothills of the firm’s long-term strategy for generic formulations and grows its footprints in the Chinese pharmaceuticals market.

Speaking on which, Dr. Arun Chandavarkar, Joint Managing Director and CEO, Biocon, said that the company is thrilled to join CMS and this venture will enable their firm to retail its U.S. approved Generic Formulations to the Chinese patients, helping it to capitalize in the growing market.

Source Credit: https://www.moneycontrol.com/news/business/biocon-subsidiary-acquires-research-facility-from-pfizer-healthcare-4468051.html

About Author

Pankaj Singh

Pankaj Singh

Endowed with a post graduate degree in management and finance, Pankaj Singh has been a part of the online content domain for quite a while. Having worked previously as a U.K. insurance underwriter for two years, he now writes articles for fractovia.org and other online portals. He can be contacted at- [email protected] | https://twitter.com/PankajSingh2605

Related News

Revival in UK hotel bookings after COVID-19 downturn, says Premier Inn

Published Date: 2020-07-09         Author: Pankaj Singh

UK has registered a revival in hotel bookings for conventional regional tourist destinations as people have started planning summer trips to the seaside and countryside, stated Premier Inn owner. The Chief Executive of Whitbread, Alison Brittain, has stated that larger cities like London continue... Read More

Fujitsu gravitates toward 'new normal' with new office working style

Published Date: 2020-07-08         Author: Pankaj Singh

Fujitsu Limited, a Japanese multinational IT company headquartered in Tokyo, has reportedly announced that it will boost its shift to becoming a digital transformation organization with an ambitious plan to transform the working style for its employees in Japan in the light of COVID-19 pandemic. ... Read More

Britain nears USD 625 million COVID-19 vaccine deals with Sanofi/GSK

Published Date: 2020-07-06         Author: Pankaj Singh

With over 100 vaccines are being tested and developed to stop the spread of COVID-19, it seems that governments worldwide are racing to secure supplies of vaccines even before their efficiency is proven. As per the latest news, Britain government is close to a USD 625 million supply deals with Sanof... Read More

© 2020 Fractovia. All Rights Reserved